In vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents
✍ Scribed by D. Shahbazi-Gahrouei; S. M. Rizvi; M. A. Williams; B. J. Allen
- Publisher
- Springer Netherlands
- Year
- 2002
- Tongue
- English
- Weight
- 106 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0158-9938
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract New tumor‐specific contrast agents for clinical imaging and therapy for cancer are required. To this end Gd‐H (Gd‐hematoporphyrin), Gd‐TCP (Gd‐tetra‐carboranylmethoxyphenyl‐porphyrin), Gd‐DTPA‐WM53, and Gd‐DTPA‐9.2.27 were synthesized and administered by systemic injection to nude mice
A highly specific and powerful magnetic resonance imaging contrast agent has been prepared by coating magnetite (Fe,O,) particles with monoclonal antibodies directed against a tumor antigen. The preparation maintains both the immunoreactivity of the monoclonal antibody and the full relaxing capabili
The introduction of a lipophilic moiety into the gadolinium chelate Gd-DTPA (dimeglumine gadopentetate, Magnevist) yielded Gd-EOB-DTPA (short form), which has potential as a magnetic resonance contrast agent for liver mass screening. The pharmacokinetics of Gd-EOB-DTPA in rats is nonlinear because a